EC[ON]OMY

Kazakhstan’s Pharmaceutical Market Growth in 2024

Kazakhstan’s pharmaceutical market showed stable growth from January to October 2024. With sales reaching 1 152.6 billion tenge, the market has reinforced its position as a key player in Central Asia. The growth is driven by local production development, expanded retail networks, and strong government support. However, alongside these achievements, new challenges are emerging, requiring strategic responses.

Kazakhstan’s pharmaceutical market is divided into two main segments: public procurement and retail sales.

The public segment accounts for 42% of total sales. This is one of the highest rates in the region. Government procurement programs focus on ensuring access to essential medicines for socially vulnerable groups.

The retail segment comprises 58% of the market. It continues to grow due to the expansion of pharmacy chains and improved consumer purchasing power. The availability of medicines for a broader population and the diversification of products are key factors driving growth.

In Russia public procurement accounts for 39%, ensuring market stability but increasing dependency on international producers.

The average price increase for pharmaceutical products in Kazakhstan reached 16% during the period.

This was driven by exchange rate fluctuations and rising import costs. Sales in physical units (packages) grew by 5%, reflecting stable demand despite higher prices.

In Russia, prices also rose by 16%, with sales volumes in physical units remaining stable. This indicates resilience to changing economic conditions.

The market features a strong mix of local and international players. The top companies include:

• SANTO, with a 4.97% market share.

• Sanofi, accounting for 4.94%.

• STADA, holding 4.16%.

• Haleon, showing a 43% growth rate.

• NOBEL-AFF, securing 4.17% by focusing on localized production.

Local producers command 17% of the market, demonstrating growing competitiveness and market share expansion.

In Russia local producers account for 35-36%, though their growth is constrained by competition with international brands.

The market maintains a balanced structure:

• Prescription drugs (Rx) account for 60-70% of total sales. These products are essential for treating chronic and complex conditions.

• Over-the-counter (OTC) medications comprise the remaining share. Their popularity is driven by affordability, accessibility, and active marketing.

Despite steady growth, Kazakhstan’s pharmaceutical market faces new challenges:

1. Intensifying competition. International brands dominate through strong marketing and logistics. Local companies must invest in technology and diversify their product portfolios.

2. Rising import costs. Exchange rate fluctuations are driving up medicine prices, potentially limiting accessibility.

3. Limited local production. Local manufacturers currently lack a broad range of innovative and prescription drugs.

4. Skilled labor shortages. The market needs more professionals trained to meet international standards.

5. Threats from counterfeit products. Poorly controlled imports risk undermining market trust and patient safety.

To address these challenges, the market should focus on:

• Strengthening local production with an emphasis on innovative and prescription drugs.

• Expanding product diversity to enhance competitiveness.

• Building partnerships with educational institutions to train skilled professionals.

• Enhancing quality control to combat counterfeit products.

• Promoting exports of local medicines to strengthen Kazakhstan’s international position.

Kazakhstan’s pharmaceutical market holds significant potential to remain a leader in Central Asia. However, overcoming emerging challenges will require coordinated efforts from all industry stakeholders.

 

Guldariya Manakpaeva, Executive Director of the “PharmMedIndustry Kazakhstan” Association

Scroll to Top